Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis

The present study focused on the association of early bevacizumab (Bev) interruption with the clinical outcome of atezolizumab plus bevacizumab.

[1]  J. Ferlay,et al.  Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.

[2]  J. Llovet,et al.  Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Zhu,et al.  Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Yulei N. Wang,et al.  Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. , 2020, The Lancet. Oncology.

[5]  J. Marrero,et al.  Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference , 2020, Hepatology.

[6]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[7]  M. Kudo,et al.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[8]  Gisela Schwab,et al.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.

[9]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[10]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[11]  P. Hegde,et al.  Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. , 2017, Seminars in cancer biology.

[12]  M. Kudo,et al.  Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function , 2017, Liver Cancer.

[13]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[14]  Suzanne F. Jones,et al.  Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma , 2016, Nature Communications.

[15]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Tartour,et al.  VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors , 2015, The Journal of experimental medicine.

[17]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[18]  J. Pignon,et al.  Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. , 2012, The oncologist.

[19]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[20]  S. Paggi,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[21]  S. Rafii,et al.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Carbone,et al.  Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. , 1998, Journal of immunology.

[23]  P. Hansell,et al.  Leukocyte adhesion in angiogenic blood vessels. Role of E-selectin, P-selectin, and beta2 integrin in lymphotoxin-mediated leukocyte recruitment in tumor microvessels. , 1997, The Journal of clinical investigation.

[24]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[25]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[26]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.